Liver Transplantation Outcomes of HBV-, HCV-, and Alcohol-induced Hepatocellular Carcinoma in the United States: Analysis of National Inpatient Samples

Abstract

Objective

Liver transplantation is a current treatment option for hepatocellular carcinoma (HCC). The United States National Inpatient Sample database was utilized to identify risk factors that influence the outcome of liver transplantation, including locoregional recurrence, distant metastasis, and in-hospital mortality, in HCC patients with concurrent hepatitis B infection, hepatitis C infection, or alcoholic cirrhosis.

Methods

This retrospective cohort study included HCC patients (n=2391) from the National Inpatient Sample database who underwent liver transplantation and were diagnosed with hepatitis B or C virus infection, co-infection with hepatitis B and C, or alcoholic cirrhosis of the liver between 2005 and 2014. Associations between HCC etiology and post-transplant outcomes were examined with multivariate analysis models.

Results

Liver cirrhosis was due to alcohol in 10.5% of patients, hepatitis B in 6.6%, hepatitis C in 10.8%, and combined hepatitis B and C infection in 24.3%. Distant metastasis was found in 16.7% of patients infected with hepatitis B and 9% of hepatitis C patients. Local recurrence of HCC was significantly more likely to occur in patients with hepatitis B than in those with alcohol-induced disease.

Conclusion

After liver transplantation, patients with hepatitis B infection have a higher risk of local recurrence and distant metastasis. Postoperative care and patient tracking are essential for liver transplant patients with hepatitis B infection.

Keywords

alcoholic hepatitis / hepatocellular carcinoma / liver cirrhosis / National Inpatient Sample (NIS) / transplantation / viral hepatitis

References

[1] YangJD, HainautP, GoresGJ, et al.. A global view of hepatocellular carcinoma: trends risk, prevention and management. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 589-604

[2] Global Burden of Disease Liver Cancer CollaborationAkinyemijuT, AberaS, et al.. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol, 2017, 3(12): 1683-2691

[3] SingalAG, LamperticoP, NahonP, et al.. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol, 2020, 72(2): 250-261

[4] KulikL, HeimbachJK, ZaiemF, et al.. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. Hepatology, 2018, 7(1): 381-400

[5] YangJD, LarsonJJ, WattKD, et al.. Hepatocellular carcinoma is the most common indication for liver transplantation and placement on the waitlist in the United States. Clin Gastroenterol Hepatol, 2017, 15(5): 767-775

[6] SingalAK, GuturuP, HmoudB, et al.. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation, 2013, 95(5): 755-760

[7] CesconM, CucchettiA, GraziGL, et al.. Role of hepatitis B virus infection in the prognosis after hepatectomy for hepatocellular carcinoma in patients with cirrhosis: A Western dual-center experience. Arch Surg, 2009, 144(10): 906-913

[8] MazzaferroV, CitterioD, BhooriS, et al.. Liver transplantation in hepatocellular carcinoma after tumor downstaging (XXL): a randomized, controlled, phase 2b/3 trial. Lancet Oncol, 2021, 21(7): 947-956

[9] DugumM, HanounehI, LopezR, et al.. Hepatocellular carcinoma in the setting of chronic hepatitis B virus infection: tumor recurrence and survival rates after liver transplantation. Transplant Proc, 2015, 47(6): 1939-1944

[10] BurraP, GermaniG, AdamR, et al.. Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol, 2013, 58(2): 287-296

[11] FranssenB, AlshebeebK, TabrizianP, et al.. Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center. Ann Surg, 2014, 260(4): 650-656

[12] KrasnodębskiM, GrątM, MasiorŁ, et al.. Differential impact of risk factors for tumor recurrence in hepatitis B and hepatitis C virus-infected patients undergoing liver transplantation for hepatocellular carcinoma. Ann Transplant, 2015, 20: 70-75

[13] KuboS, TakemuraS, TanakaS, et al.. Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma. World J Gastroensterol, 2015, 21(27): 8249-8255

[14] HongSK, JinXL, SuhS, et al.. Different Risk Factors for Early and Late Recurrence After Curative Resection of Hepatocellular Carcinoma. World J Surg, 2022, 46(1): 197-206

[15] ChoudharyN, SarafN, SaigalS, et al.. Outcome of hepatitis C-related liver transplantation in direct-acting antiviral era. Indian J Gastroenterol, 2020, 39(6): 539-543

[16] UtsunomiyaT, ShimadaM, KudoM, et al.. Acomparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Ann Surg, 2015, 261(3): 513-520

[17] Overview of the Nationwide Inpatient Sample (NIS). Available at: http://www.hcup-us.ahrq.gov/nisoverview.jsp. (Accessed November 28, 2017).

[18] GiulianoAE, BallmanK, McCallL, et al.. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. Ann Surg, 2016, 264(3): 413-420

[19] MarotA, HenrionJ, KnebelJF, et al.. Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study. PLoS One, 2017, 12(10): e0186715

[20] ToshikuniN, IzumiA, NishinoK, et al.. Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis. J Gastroenterol Hepatol, 2009, 24(7): 1276-1283

[21] TandoiF, PonteE, SaffiotiMC, et al.. Liver transplantation for hepatocellular carcinoma within Milan Criteria in patients with Model for End-Stage Liver Disease score below 15: the impact of the etiology of cirrhosis on long-term survival. Transplant Proc, 2013, 45(7): 2711-2714

[22] GroeschlRT, HongJC, ChristiansKK, et al.. Viral status at the time of liver transplantation for hepatocellular carcinoma: a modern predictor of long-term survival. HPB (Oxford), 2013, 15(10): 794-802

[23] Centers for Disease Control and Prevention. Surveillance for Viral Hepatitis–United States, 2015. Available at: https://www.cdc.gov/hepatitis/statistics/2015surveillance/index.htm. Accessed January 2, 2018.

[24] SharmaSK, SainiN, ChwlaY. Hepatitis B virus: inactive carriers. Virol J, 2005, 2: 82